Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Tuspetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aptose Reports First Quarter 2026 Results
    Aptose Reports First Quarter 2026 Results

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3294501/35575/en/aptose-reports-first-quarter-2026-results.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Aptose Gets Court OK for Arrangement Plan; Reports FY2025
    Aptose Gets Court OK for Arrangement Plan; Reports FY2025

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3266139/35575/en/Aptose-Biosciences-Announces-Results-of-Special-Shareholders-Meeting-Announces-Receipt-of-Final-Court-Approval-of-Plan-of-Arrangement-Reports-Year-End-2025-Results-and-Corporate-Hi.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    Aptose Spotlights Tuspetinib's AML Responses at ASH 2025
    Aptose Spotlights Tuspetinib's AML Responses at ASH 2025

    06 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/06/3201046/35575/en/Aptose-s-Tuspetinib-Triple-Drug-Therapy-Featured-at-the-2025-ASH-Annual-Meeting-High-Rate-of-Frontline-Clinical-Responses-Continues-Across-AML-Populations.html

    GLOBENEWSWIRE
    06 Dec 2025
    Share Share
    Aptose Reports Third Quarter 2025 Results
    Aptose Reports Third Quarter 2025 Results

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187912/35575/en/Aptose-Reports-Third-Quarter-2025-Results.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    Aptose Tuspetinib Data In Newly Diagnosed AML Chosen For ASH
    Aptose Tuspetinib Data In Newly Diagnosed AML Chosen For ASH

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179367/35575/en/Aptose-Tuspetinib-Clinical-Data-from-Ongoing-TUSCANY-Trial-in-Newly-Diagnosed-AML-Selected-for-Presentation-at-the-2025-ASH-Annual-Meeting.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Aptose’s Tuspetinib Excels with Standard Care in AML Patients
    Aptose’s Tuspetinib Excels with Standard Care in AML Patients

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167802/35575/en/Aptose-s-Tuspetinib-Exceeds-Expectations-When-Combined-with-Standard-of-Care-Treatment-Across-Diverse-Populations-of-Newly-Diagnosed-AML.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.